Eye & ENT Hospital of Fudan University

CRISPR-Cas Clinical Trial Update
Nov. 17, 2020

We have added 4 new CRISPR-Cas trials to our overview of current clinical trials involving gene editing.

Eye & ENT Hospital of Fudan University

Congenital Hearing Loss, (NCT06025032)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Neovascular Age-related Macular Degeneration, nAMD, (NCT06031727)
Sponsors:
HuidaGene Therapeutics Co., Ltd.
Indicator
IND Enabling
Phase I
Phase II
Phase III
Herpes Simplex Virus Refractory Keratitis, (NCT04560790)
Sponsors:
Shanghai BDgene Co., Ltd.
IND Enabling
Phase I
Phase II
Phase III
close
Search CRISPR Medicine